
Index

- Acetoacetate, glucose metabolism and, 15
Adipocytes, 8-9
Adipose tissue, fatty acid mobilization by, 5-6
Aerobic capacity, maximum, 35-38
Alpha-adrenergic receptor blockade, 59-60
Amino acid uptake by muscle, 19-22
 α -Aminoisobutyric acid (AIB), 19-20
ATPase, myosin, 28
- Beta-adrenergic receptor blockade, 59-60
Binding process, 11
Blood flow in exercise, 33-38, 71, 72
Blood glucose
 concentration during exercise, 59
 levels, 1, 6
- cAMP, plasma, exercise-induced changes in, 39, 40
Capillary
 diffusion capacity and filtration coefficient, 104
 supply of skeletal muscle, 94, 97
Carbohydrate
 and fat interrelationships in muscle, 6-7
 stores of body, 82
 utilization in muscle, 4-5
Cardiac output, 33-37
Catecholamines, 108
 diabetes mellitus and, 61-62
 exercise and, 58-62
 insulin secretions and, 60
Cholesterol, 90-92
Contractile activity, 19
- Diabetes
 chemical, 30-32
 exercise and, overview of, 107-110
 exercise in, beneficial effects of, 87
 glucose utilization in, 83-84
 juvenile, muscle fiber characteristics in, 95, 97-99
 maturity-onset, physical training and, 89-92
 mellitus, catecholamines and, 61-62
 mellitus, free fatty acid and ketone body metabolism in, 67-69
 splanchnic glucose production and, 85-86
Diabetic microangiopathy, 103-106
 exercise testing to detect, 105
Diabetic patients, exercise studies in, 55-57, 103-104
- Electromyography (EMG), 96
Energetics, review of, 33-38
Energy mobilization in exercise in dogs, 39-44
Epinephrine
 exercise and, 58-62
 glycogenolysis and, 40-43
Exercise, 107; *see also* Training, physical
 blood flow in, 33-38
 blood glucose concentration during, 59
 in blood glucose homeostasis, 84-85
 catecholamines and, 58-62
 in diabetes, beneficial effects of, 87
 diabetes and, overview of, 107-110
 in diabetic men, insulin in, 76-81
 diabetic microangiopathy and, 103-106
 in dogs, energy mobilization in, 39-44
 in dogs, glucose fluxes during, 45-52
 effects on diabetics, 103-104
 free fatty acid metabolism during, 66-67
 fuel utilization during, 1-7
 glucoregulation during, 46
 glucose homeostasis and, 50-51
 glucose ingestion in connection with, 86, 87
 glucose metabolism and, 104
 glucose oxidation during, 64
 glucose turnover during, 82-88, 109
 glucose utilization in, 14
 glycemic response to, 78-79

- hepatic glucose production during, 71-75
 hormonal response to, 84
 hyperglycemic effect of, 46
 immunoreactive insulin during, 79, 80
 -induced hypoglycemia, mechanism for, 57
 insulin administration and, 87
 insulin and, 53-57
 lactate oxidation in, 14-15
 muscle metabolism during, 98-99
 physiologic responses to, 35-38
 plasma glucose during, 76
 plasma lactate and glucose levels during, 55-56
 studies in diabetic patients, 55-57
 testing to detect diabetic microangiopathy, 105
- Fat and carbohydrate interrelationships in muscle, 6-7
- Fatty acids, 13, 15, 16
 free, 79
 free, metabolism at rest, 66, 67
 free, metabolism during exercise, 66-70
 free, release, in exercising dogs, 39-44
 mobilization by adipose tissue, 5-6
 oxidation, 3
- Fiber types and metabolic patterns, 28
- Flux-generating steps, 2-3
- Fructose-1,6-bisphosphatase (FDPase) activity, 27
- Fuel utilization during exercise and starvation, 1-7
- Glucagon, 104
 during exercise, 72
 during exercise in dogs, 45-52
 glucose and, 47
 hepatic glucose production and, 71-75
 immunoreactive, insulin and, 46-51
 levels, energy mobilization and, 41-43
 receptor, 9-10
- Gluconeogenesis, 85-86, 109
- Glucoregulation during exercise, 46
- Glucose
 arterial, during exercise, 72-74
 disappearance, 79,90
 disposition in starvation, 14-15, 16
 fluxes during exercise in dogs, 45-52
 glucagon and, 47
 homeostasis, blood, 84-85
 homeostasis, exercise and, 50-51
 ingestion in connection with exercise, 86, 87
 level, blood, 1, 6
 levels during exercise in diabetic patients, 55-56
 metabolism, acetoacetate and, 15
 metabolism, exercise and, 104
 metabolism, splanchnic, 72-74
 naturally labeled, 63-65
 oxidation during exercise, 64
 oxidation rates of exogenous, 63-65
 plasma, exercise-induced changes in, 39-40, 76
 production, hepatic, 71-75
 production, insulin and, 50-51
 protein breakdown and, 22
 tolerance, intravenous, 90
 tolerance test, oral (OGTT), 30-32, 90, 91
 tolerance tests at rest, 63-64
 turnover, calculation of, 78
 turnover during exercise of, 82-88, 109
 utilization, 48
 utilization by skeletal muscle, 13-14, 82-83
 utilization in diabetes, 83-84
 utilization in exercise, 14
- Glucose-6-phosphate, 98
- Glycemic response
 to exercise, 78-79
 in relation to insulin injection site, 79, 80
- Glycerol, 79
- Glycogen, depletion of, 96-99
- Glycogenolysis, 83
 epinephrine and, 40-43
 regulation of, 100-102
- Glycolysis, 100-101
 during sprinting, 1-2
- Growth hormone, 104
 measurement of, 10
- Heart rate, maximum, 37-38
- Hexokinase activity, 31, 32, 97
- Hormonal response to exercise, 84
- Hormone receptor
 interactions, 8-12
 regulation of, 8-9
- β -Hydroxybutyrate, 79
- Hypertrophy, muscle, 18-24, 108
- Hypoglycemia
 exercise-induced, mechanism for, 57
 insulin supply and, 47
 mechanism of, 45-52
- Hyperglycemic effect of exercise, 46
- Insulin
 administration and exercise, 87
 amino acid uptake by muscle and, 19-22
 arterial, during exercise, 72-74
 exercise and, 53-57
 exercise in diabetic men and, 76-81
 exercise in dogs and, 45-52
 glucose production and, 50-51
 hepatic glucose production and, 71-75
 immunoreactive, during exercise, 79, 80
 immunoreactive glucagon and, 46-51
 injection site, glycemic response in relation to, 79, 80
 -like activities, nonsuppressible (NSILA), 10
 plasma, energy mobilization and, 41-43
 protein breakdown and, 22-24
 receptors, 8-12, 107
 resistance, 9
 resistance, obesity and, 32
 secretion, catecholamines and, 60
 supply, hypoglycemia and, 47
- Ketone bodies, 13, 15, 16, 108
 metabolism of, during exercise, 66-70

- Lactate
 activity, 98
 concentrations, 78, 79
 dehydrogenase (LDH) activity, 26, 27
 levels during exercise in diabetic patients, 55-56
 oxidation in exercise, 14-15
 plasma, exercise-induced changes in, 39, 40
 production, 100-101, 103
 release of, 83
- Lipids, plasma, 90-92
- Lipolysis in adipose tissue, 6
- Malate dehydrogenase (MDH) activity, 26-27
- Metabolic
 control, sensitivity in, 3-4
 functions, anaerobic and aerobic, 25
 pathway, 3
 patterns, fiber types and, 28
- Microangiopathy, diabetic, *see* Diabetic microangiopathy
- Monocytes, 8-9
- Muscle, *see also* Skeletal muscle
 capillaries, 31
 carbohydrate utilization in, 4-5
 fat and carbohydrate interrelationships in, 6-7
 fiber characteristics, 93-99
 fiber types, 26
 fibers, enzymatic analysis of single, 26-28
 fibers, metabolic subpopulations of, 25-29
 fibers, red and white, 93
 fibers, slow-twitch and fast-twitch, 93-98
 fuel utilization during exercise and starvation, 1-7
 glucose utilization by, 82-83
 hypertrophy, 108
 metabolic types of, 25
 metabolism during exercise, 98-99
 wasting, 18
 working, oxygen uptake in, 33-38
- Muscular activity and protein degradation, 20-22
- Neuropathy, experimental sympathetic, 60-61
- Norepinephrine, 108
 energy mobilization and, 41-43
 exercise and, 58-62
- Obesity, insulin resistance and, 32
- 3-OH-acyl-CoA dehydrogenase (HAD) activity, 27
- Oleic acid uptake, 67
- Oxidation rates of exogenous glucose, 63-65
- Oxygen
 saturation, pulmonary arterial, 58, 59
 uptake in exercise, 71, 72
 uptake in working muscle, 33-38
- Phentolamine, 43, 59, 60
- Phosphofructokinase, 5, 6
- Phosphorylase
 activation, 100-101
 hepatic, 3
- Physical training, *see* Training, physical
- Plasma volume decline, 105
- Propranolol, 42-43, 59-60, 108
- Protein
 breakdown, glucose and, 22
 breakdown, insulin and, 22-24
 degradation, muscular activity and, 20-22
- Proteinuria, 104, 105
- Pulse tracing, arterial, 105
- Pyruvate
 concentrations, 78, 79
 dehydrogenase (PDH), 15, 108
 dehydrogenase (PDH) activation, 101-102
 oxidation, 100-102
- Radioreceptor assay, 8, 10
- Resistance, insulin, *see* Insulin resistance
- Rest
 free fatty acid metabolism at, 66, 67
 glucose tolerance tests at, 63-64
- Scatchard plot, 10
- Sensitivity in metabolic control, 3-4
- Skeletal muscle, *see also* Muscle
 capillary supply of, 94, 97
 glucose utilization by, 13-14
 glycogenolysis and pyruvate oxidation in, 100-102
 substrate utilization in perfused, 13-17
- Somatostatin, 43
- Splanchnic glucose
 metabolism, 72-74
 production, diabetes and, 85-86
- Sprinting, glycolysis during, 1-2
- Starvation
 fuel utilization during, 1-7
 glucose disposition in, 14-15, 16
- Substrate utilization in perfused skeletal muscle, 13-17
- Succinate dehydrogenase, 31, 32
 activity, 94, 95, 98
- Training, physical, *see also* Exercise
 chemical diabetes and, 30-32
 in maturity-onset diabetes, 89-92
 one-legged, 95-96
 programs, 110
- Triglycerides, 66
 plasma, 90-92
- Tyrosine, 21